#1 Clinical Trials Search in Europe

Autologous Blood-Derived Endothelial Progenitor Cells, Haematopoietic Stem/Progenitor Cells, Activated Dendritic Cells And T Helper Cells

This article discusses an innovative clinical trial investigating the use of BGC101, a unique cell therapy composed of autologous blood-derived cells, for treating peripheral arterial disease (PAD) with critical limb ischemia (CLI). The study aims to evaluate the safety and effectiveness of this advanced therapy in patients who have not responded to standard treatments or are not candidates for further revascularization procedures.

Table of Contents

What is BGC101?

BGC101, also known as EnEPC, is an innovative medical treatment being studied for patients with severe circulatory problems in their legs. It is classified as an Advanced Therapy Investigational Medicinal Product (ATIMP), which means it’s a cutting-edge therapy that uses cells from your own body to potentially treat disease.[1]

The full name of this treatment is quite complex: Autologous Blood-Derived Endothelial Progenitor Cells, Haematopoietic Stem/Progenitor Cells, Activated Dendritic Cells and T Helper Cells. Let’s break this down:

  • Autologous: This means the cells come from your own body
  • Blood-Derived: The cells are taken from your blood
  • Endothelial Progenitor Cells: These are cells that can grow into the lining of blood vessels
  • Haematopoietic Stem/Progenitor Cells: These are cells that can develop into various types of blood cells
  • Activated Dendritic Cells and T Helper Cells: These are important cells in your immune system

Medical Conditions Treated

BGC101 is being studied to treat two related conditions:[1]

  1. Peripheral Arterial Disease (PAD): This is a condition where the arteries in your legs become narrowed, reducing blood flow to your legs and feet.
  2. Critical Limb Ischemia (CLI): This is an advanced stage of PAD where the reduced blood flow is so severe that it causes pain, even when resting, and can lead to sores or gangrene.

Specifically, BGC101 is being tested for patients with these conditions who have not responded to standard treatments and are not candidates for procedures to restore blood flow (revascularization).

How BGC101 Works

While the exact mechanism is still being studied, BGC101 is designed to use your body’s own cells to potentially improve blood flow in your legs. The treatment is given as an intramuscular injection, which means it’s injected directly into the muscles of the affected leg.[1]

The different types of cells in BGC101 may work together to:

  • Help form new blood vessels
  • Improve existing blood flow
  • Support healing and reduce inflammation

Clinical Trial Details

BGC101 is currently being tested in a Phase 1/2 clinical trial. This means it’s in the early stages of research in humans. The trial has two parts:[1]

  1. A small pilot study with 5 patients to test the safety of BGC101
  2. A larger study with 45 patients to further test safety and begin to assess how well it works

In the larger study, patients will be randomly assigned to receive either BGC101 or a placebo (a treatment with no active ingredients) in a 2:1 ratio. This means for every two patients who receive BGC101, one will receive the placebo.

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key points include:[1]

  • Be at least 18 years old
  • Have severe PAD with CLI (specifically, Rutherford category 4-5)
  • Not be a good candidate for standard treatments to restore blood flow, or have had unsuccessful treatments
  • Not have certain other health conditions that might interfere with the treatment or its evaluation

There are also several conditions that would prevent someone from participating in the study, such as recent heart problems, severe kidney or liver disease, or certain infections.

Safety and Efficacy Measures

The researchers will be closely monitoring several aspects of patient health to assess the safety and effectiveness of BGC101:[1]

Safety Measures:

  • Side effects, especially those related to the injection
  • Serious adverse events
  • Changes in vital signs and laboratory tests
  • How well the injection site tolerates the treatment

Efficacy Measures:

  • The rate of major amputations (below or above the knee) after 12 months
  • The rate of survival without major amputation after 12 months

Potential Benefits

While it’s important to remember that BGC101 is still in the research phase and its benefits are not yet proven, the hope is that this treatment could potentially:[1]

  • Improve blood flow in the legs of patients with severe PAD and CLI
  • Reduce pain and improve wound healing
  • Decrease the need for amputations
  • Improve quality of life for patients who have not responded to other treatments

As with any experimental treatment, it’s crucial to discuss the potential risks and benefits with your healthcare provider if you’re considering participating in this or any clinical trial.

Aspect Details
Study Type Phase 1/2, open-label & double-blind randomized placebo-controlled
Investigational Product BGC101 (EnEPC) – Autologous blood-derived cell therapy
Target Condition Peripheral Arterial Disease (PAD) with Critical Limb Ischemia (CLI)
Primary Objectives Evaluate feasibility, safety, and efficacy of BGC101
Key Inclusion Criteria Adults 18+, Rutherford category 4-5, specific hemodynamic indicators
Primary Endpoints Safety: Adverse events, vital signs, laboratory values
Efficacy: Major amputation rate and amputation-free survival at 12 months
Study Design Two parts: Pilot open-label (5 patients), Double-blind randomized (45 patients)

FAQ

  • What is BGC101 and how does it work? BGC101 is an advanced cell therapy made from a patient's own blood cells, including endothelial progenitor cells, hematopoietic stem/progenitor cells, activated dendritic cells, and T helper cells. It is designed to promote blood vessel growth and improve circulation in patients with severe PAD and CLI.
  • Who is eligible for this clinical trial? The trial is open to adults aged 18 and older with PAD and CLI who have not responded to standard treatments or are not candidates for further revascularization procedures. Specific criteria include having a Rutherford category 4-5 and meeting certain hemodynamic indicators of severe peripheral arterial occlusive disease.
  • What are the main objectives of the study? The primary objectives are to assess the feasibility, safety, and efficacy of BGC101 in treating PAD with CLI. The study will evaluate the incidence of adverse events, major amputation rates, and amputation-free survival at 12 months.
  • How is the study designed? The study is conducted in two parts: a pilot, first-in-human, open-label study with 5 patients, followed by a larger double-blind, randomized, placebo-controlled study with 45 patients. This design allows for initial safety assessment before moving to a more comprehensive evaluation.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include improved blood circulation and reduced risk of amputation. Risks may include injection site reactions and other adverse events related to the treatment. The study closely monitors participants' safety through various assessments, including vital signs, physical examinations, and laboratory tests.

Ongoing Clinical Trials on Autologous Blood-Derived Endothelial Progenitor Cells, Haematopoietic Stem/Progenitor Cells, Activated Dendritic Cells And T Helper Cells

  • Study on BGC101 for Treating Peripheral Arterial Disease with Critical Limb Ischemia in Patients Not Responding to Standard Treatments

    Not recruiting

    2 1
    Investigated drugs:
    Belgium

Glossary

  • Peripheral Arterial Disease (PAD): A circulatory condition where narrowed arteries reduce blood flow to the limbs, often causing leg pain and other symptoms.
  • Critical Limb Ischemia (CLI): An advanced stage of PAD characterized by severe blockage in the arteries of the lower extremities, significantly reducing blood flow and potentially leading to tissue loss.
  • Autologous: Derived from the same individual; in this context, it refers to cells taken from the patient's own body.
  • Endothelial Progenitor Cells: Cells that can develop into endothelial cells, which line the interior surface of blood vessels.
  • Hematopoietic Stem/Progenitor Cells: Immature cells that can develop into various types of blood cells.
  • Dendritic Cells: Immune cells that process and present antigens to other cells of the immune system.
  • T Helper Cells: A type of white blood cell that plays a central role in the immune system.
  • Revascularization: A surgical procedure to restore blood flow to a body part or organ.
  • Rutherford Category: A classification system used to assess the severity of peripheral arterial disease.
  • WIfI Classification: A system used to assess wound, ischemia, and foot infection in patients with PAD and diabetic foot problems.
  • Amputation-free Survival (AFS): A measure of how long a patient lives without requiring a major amputation.
  • Advanced Therapy Investigational Medicinal Product (ATIMP): A type of medicine based on genes, tissues, or cells, used in clinical trials to treat various conditions.

References

  1. http://clinicaltrials.eu/trial/study-on-bgc101-for-treating-peripheral-arterial-disease-with-critical-limb-ischemia-in-patients-not-responding-to-standard-treatments/